Related Experiment Videos
Complete remission of cryoglobulinemic glomerulonephritis (HCV-positive) after high dose interferon therapy
M Laganović1, B Jelaković, D Kuzmanić
1Department of Internal Medicine, University Hospital Center Zagreb, Croatia. mario.laganovic@zg.tel.hr
Insights
High-dose interferon alpha effectively treated cryoglobulinemic glomerulonephritis in a hepatitis C patient, achieving remission. Re-evaluating standard interferon alpha dosages for this condition is recommended.
Area of Science:
- Nephrology
- Hepatology
- Immunology
Background:
- Hepatitis C virus (HCV) infection can lead to mixed cryoglobulinemia, a condition associated with glomerulonephritis.
- Cryoglobulinemic glomerulonephritis presents a complex clinical challenge, often requiring targeted antiviral and immunosuppressive therapies.
Observation:
- A 64-year-old woman with HCV and mixed cryoglobulinemia type II developed cryoglobulinemic glomerulonephritis.
- Initial treatment with standard-dose interferon alpha-2b achieved remission but relapsed upon cessation.
- High-dose interferon-alpha therapy (5 million units thrice weekly for 9 months) resulted in sustained clinical and virologic remission.
Findings:
- High-dose interferon-alpha monotherapy demonstrated efficacy in achieving prolonged remission for cryoglobulinemic glomerulonephritis.
- The patient experienced normalization of liver enzymes (AST, ALT) and significant reduction in proteinuria.
- Sustained virologic response was observed after high-dose interferon-alpha treatment.
Implications:
- Standard interferon-alpha dosage and duration for cryoglobulinemic glomerulonephritis may require re-evaluation.
- High-dose interferon-alpha is a viable therapeutic option for managing cryoglobulinemic glomerulonephritis.
- While interferon-alpha monotherapy showed success, combination therapy with ribavirin is increasingly supported for chronic HCV infections.
Abstract:
We report the case of a 64-year old woman with hepatitis C virus infection, mixed cryoglobulinemia type II (IgG + IgM kappa) and cryoglobulinemic glomerulonephritis. The patient was treated with the standard dose of recombinant interferon alpha-2b (3 million units 3 times a week) for one year, resulting in complete clinical remission and undetectable levels of serum hepatitis C virus RNA. AST and ALT normalized and proteinuria decreased from 2.78 to 0.98 g/day. However, a relapse occurred when therapy was stopped. Additional therapy with interferon-alpha (5 million units 3 times a week for 9 months) resulted again in quick and prolonged remission. The clinical course of our patient showed sustained clinical and virologic response after high-dose interferon-alpha treatment confirming the usefulness of interferon alpha in treatment of patients with cryoglobulinemic glomerulonephritis. Our observation is in agreement with others, suggesting that recommended standard dosage and duration of initial treatment with interferon alpha should be re-evaluated. Although our patient had sustained virologic and clinical response after interferon alpha monotherapy, recent studies clearly support combination therapy of interferon alpha and ribavirin for treatment of chronic HCV infections.